Search results
Showing 856 to 870 of 973 results for death
NICE has developed a Medtech Innovation Briefing (MIB) on the Space GlucoseControl system for managing blood-glucose in critically ill patients in intensive care
Early and locally advanced breast cancer: diagnosis and management (NG101)
This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.
Late stage assessment (LSA) guidance on transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis.
View recommendations for HTG757Show all sections
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making